跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 24 条关于
“INTP23”
全部
24
临床试验
12
药物
1
机构
0
资讯
11
去年
Amgen Settles Denosumab Biosimilar Patent Dispute with Accord BioPharma
去年
Intensity Therapeutics' Sarcoma Trial INT230-6 Authorized to Continue by DMC
2年前
Intensity Therapeutics Initiates Phase 3 Trial of INT230-6 for Metastatic Sarcoma
2个月前
Intensity Therapeutics' INT230-6: Turning Solid Tumors Into Personalized Anti-Cancer Vaccines
去年
Intensity Therapeutics' INT230-6 Shows Promise in Localized Cancer Reduction and Systemic Immune Activation
去年
Intensity Therapeutics' Novel Cancer Drug INT230-6 Shows Promise in Advanced Sarcoma and Breast Cancer
10个月前
Intensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Metastatic Cancers
9个月前
Intensity Therapeutics Reports Improved Safety Profile for INT230-6 in Triple Negative Breast Cancer Trial
去年
Intensity Therapeutics and SAKK Initiate Phase 2 Trial of INT230-6 in Triple-Negative Breast Cancer
10个月前
Intensity Therapeutics Stock Surges 400% Following Promising Phase I/II Data for INT230-6 in Solid Tumors
第 1 页,共 2 页
上一页
下一页